CD163 and anemia (phenotype): Based on anemia and the percentage of CD163+EPOR+ TAMs, patients were classified into four arms, as follows: Arm 1, no anemia, and the percentage of CD163+EPOR+TAMs < 2.5; Arm 2, anemia, and the percentage of CD163+EPOR+TAMs < 2.5; Arm 3, no anemia, and the percentage of CD163+EPOR+TAMs ≥ 2.5; Arm 4, anemia, and the percentage of CD163+EPOR+TAMs ≥ 2.5; The mDFS for Arms 1-4 were 41.0, 36.7, 25.7, and 29.6 months, respectively (Figure 8(c)); The mOS for Arms 1-4 were 42.0, 39.6, 33.8, and 35.3 months, respectively (Figure 8(d)).